Abstract Invasive pulmonary aspergillosis (IPA) is a fungal infection that is seen with particular frequency in immunocompromised patients, and associated with high rates of mortality. To combat or prevent IPA, triazoles such as voriconazole or itraconazole and posaconazole have become accepted as firstand second-line therapy, respectively. However, triazoles are associated with issues of oral bioavailability, high liver metabolism, and/or drug-drug interactions, increasing the variability of systemic concentrations. As a way to overcome these issues, inhalation appears to be a promising route for delivery of triazoles for prophylactic or curative therapy in IPA. Indeed, pulmonary drug delivery drastically increases the drug in situ while decreasing the systemic exposure, thereby limiting drug metabolization, side effects, and drug-drug interactions. The development of triazoles for inhalation has focused on voriconazole and itraconazole, drugs which are both highly permeable but with significant different solubility. In this review, we describe the most advanced and promising pharmaceutical developments for voriconazole and itraconazole.
Introduction
Among the various pulmonary fungal infections, aspergillosis -and invasive pulmonary aspergillosis (IPA) in particularrepresents a serious threat for immunocompromised patients, and associated with high rates of morbidity and mortality. Indeed, IPA represents 50-60 % of all invasive pulmonary diseases and is fatal in 50-90 % of cases in severely immunocompromised patients [1] . Triazoles act by inhibiting 14-α demethylase, a fungal cytochrome P450 enzyme implicated in the synthesis of ergosterol, an essential constituent of the fungal cell wall. In addition, they interact with the same cytochrome present in large quantities in the human liver, potentially inducing drug-drug interactions in IPA patients [2, 3] . Interactions resulting from inhibitors, inductors, or substrates of cytochromes can modify the plasma concentrations of triazoles or others drugs administered concomitantly. Moreover, the genetic polymorphism can also have unexpected effects on the plasma pharmacokinetic profile. To overcome these important issues, pulmonary delivery of triazoles could be an interesting alternative to conventional routes.
Pulmonary Aspergillosis
The term aspergillosis includes various diseases caused by ubiquitous saprophyte fungi of the Aspergillus type. In view of the large number (approximately 900) of species of Aspergillus, it is important to note that the majority of aspergillosis diseases are caused by four species in particular: A. fumigatus (65-75 %), A. flavus (5-10 %), A. niger (1.5-3 %) and A. terreus (2-3 %) [2, 4] . Aspergillus contamination in 90 % of cases occurs with the entry of spores into the body through the respiratory system [2] . Indeed, Aspergillus spores are of a respirable size (1.9-6 microns) that can be inhaled and deposited deep in the lungs [5] . Healthy individuals, despite inhaling a few hundred Aspergillus spores every day, usually do not develop pulmonary aspergillosis [4] [5] [6] [7] . An immunocompetent person is able to eliminate these intrusions through the mucociliary escalator, the alveolar macrophages, and/or the immune system, for example, via neutrophils [7] [8] [9] . In immunocompromised patients or in specific bronchial diseases, Aspergillus spores deposited in the lungs can be only partially eliminated, or cannot be eliminated at all, and can germinate into hyphae-inducing pulmonary aspergillosis such as aspergilloma, allergic bronchopulmonary aspergillosis, chronic necrotizing aspergillosis, or IPA [2] . In recent decades, the incidence of IPA (and opportunistic aspergillosis in general) has dramatically increased due to the increased number of immunocompromised patients [1] . Indeed, severe neutropenia (<500 cells/blood microliter) due to long corticosteroid therapy (>3 weeks), organ transplantation, leukemia, cytotoxic chemotherapy, and the presence of HIV are important risk factors for IPA [4, [10] [11] [12] . According to the immunodeficiency of the host, hyphae will grow and, by infiltration of the lung tissue, will spread to other organs such as the liver, kidneys, brain, and heart [2, 9] . Once dissemination occurs, the survival rate of treated patients is less than 10 % [3] . Hyphae are responsible for the majority of symptoms and produce toxins inhibiting mucociliary and macrophage activities, reducing clearance systems present in the lungs [9, 13] . In mild to moderate neutropenia (500-1,500 cells/blood microliter), neutrophils are able to combat or limit the fungal infection, but still generate a strong inflammatory response and pulmonary lesions, which may be fatal. Diagnosis of this pathology is carried out by radiography and by isolating Aspergillus by endoscopy, with a positive polymerase chain reaction analysis. For patients with severely neutropenia or high-risk patients, an evocative radiographic aspect is sufficient to start treatment due to the high mortality rate associated with IPA [10, 12, 14] .
Conventional Treatment of Severe Pulmonary Aspergillosis
Among the five existing antifungal classes, the genus Aspergillus is sensitive to only three, including polyenes (e.g., amphotericin B), azoles (e.g., fluconazole, itraconazole, voriconazole, and posaconazole), and echinocandins (e.g., caspofungin, micafungin, and anidulafungin). The recommendation of the Infectious Diseases Society of America (IDSA) for severe pulmonary aspergillosis such as chronic necrotizing aspergillosis and IPA is primary therapy with voriconazole (VCZ) [15, 16] . Indeed, VCZ shows better efficacy compared with amphotericin B in the treatment of IPA [17] . Alternatives for these indications are amphotericin B as a liposomal or lipid complex for patients taking medications that can interact with triazoles, such as drugs metabolized by CYP450, or in the context of triazole-resistant Aspergillus species. In the context of a disease caused by A. terreus, VCZ is preferred, as this species is resistant to amphotericin B [16] . Itraconazole (ITZ), posaconazole, caspofungin, and micafungin are also used as alternatives when primary treatment is incompatible or fails, or are used in combination to avoid the development of resistance. Antifungal combinations, however, are not routinely recommended by the IDSA [14, 16] . All of these molecules are formulated for oral (e.g., VCZ, ITZ, posaconazole) and/or parenteral administration (e.g., VCZ, ITZ, amphotericin B, caspofungin, micafungin), which may explain the higher risk of treatment failure, which can occur due to the use of high doses to obtain sufficient concentration at the pulmonary site of infection, low oral bioavailability, high liver metabolism and hepatic first-pass effect, and low blood flow to the target area due to angio-invasive hyphae of the fungus. As such, the pulmonary route is a promising alternative for the prophylactic treatment of pulmonary aspergillosis [8, 18, 19] .
Pulmonary Drug Delivery
Pulmonary administration presents several advantages for local delivery. Locally, the drug dose is readily available in situ and not diluted in the general circulation, which increases its efficacy and speed of action. Moreover, systemic exposure is reduced, reducing potential systemic side effects or drugdrug interactions. As a result, inhalation has become the preferential route of administration to treat respiratory disorders such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis, and is in development for other pulmonary disorders [18, [20] [21] [22] [23] [24] . The effectiveness of treatment via the pulmonary route is primarily dependent upon the deposition of drug-based particles and on their aerodynamic diameters (dae). The dae varies based on the geometric diameter, shape, and density of the particle. It is considered that particles with a dae of between 0.5 μm and 5 μm will be deposited in the lower airways (from the trachea up to the alveoli) during inhalation [25] [26] [27] [28] . Once deposited, particles can be cleared by various mechanisms, including the mucociliary escalator, alveolar macrophage phagocytosis, absorption through the lung epithelium, and metabolism. Mucociliary clearance occurs in the conducting zone through ciliated and goblet cells. Both carry the bronchial secretions to the pharynx, where they will be swallowed or expectorated [29] . The mucus protects the epithelium against dehydration, heats and humidifies the air, and forms a barrier against the penetration of foreign particles such as undissolved drug particles [29, 30] . In the respiratory zone, the undissolved drug particles tend to be phagocytized by alveolar macrophages [31, 32] . However, for particles greater than 6-10 μm or less than 0.2 μm in size, and/or with a hydrophilic particle surface (e.g., PEG molecules), phagocytosis appears to be prevented or reduced [33] [34] [35] . Consequently, according to their dissolution velocity, deposited drug particles can be progressively eliminated via these mechanisms or dissolved to act on their pharmacological targets and/or be metabolized or absorbed through the lung epithelium [36, 37] . Indeed, lipophilic drugs pass easily through the cell membranes of the lung epithelium by passive diffusion (transcellular transport). Hydrophilic drugs, for their part, are absorbed more slowly through extracellular channels of tight junctions by passive diffusion (paracellular transport). Some drugs may also be absorbed by active transport processes or by endocytosis, or exocytosis [28, [37] [38] [39] .
In order to achieve optimal deposition of the drug in the lungs, various formulation strategies can be applied according to the drug's physicochemical properties [40, 41•, 42, 43] . In most cases, these strategies require the use of various solvents and/or excipients during the production step. These excipients must be substances that are approved or "generally recognized as safe" (GRAS) pulmonary drug delivery [40, 44, 45] . In addition, the residual solvents must be below acceptable limits [46] . Various guidelines regarding clinical toxicity and pharmacokinetic studies of these excipients have been put forth by the Food and Drug Administration (FDA) and the International Pharmaceutical Excipients Council (IPEC) [47] [48] [49] . Each drug formulation is designed in relation to its corresponding inhalation device in order to be efficiently administered by oral inhalation. The function of inhalation devices is to deliver drug formulations reproducibly as solid or liquid particles suspended in the air (i.e., aerosol of fine particles) that present a dae between 1 and 5 μm [34, 50, 51] . There are three types of inhalation devices: nebulizers, metered pressurized dose inhalers, and dry powder inhalers (DPIs) [52] .
Pharmaceutical Development of Triazoles Delivered by Inhalation
To date, only VCZ and ITZ have been developed for inhalation against fungal infections such as pulmonary aspergillosis. The pharmaceutical development of each triazole has been described in terms of formulations for inhalation in Table 1 , and each formulation is described in Table 2 in terms of solubility/dissolution profile, in vivo pharmacokinetics, and in vivo efficacy in an immunocompromised murine model of IPA. To date, the literature reflects that formulations designed for nebulizers or DPIs have been tested only on preclinical models of IPA, and no clinical trials have been yet performed in humans.
Voriconazole
VCZ is categorized as a class II drug by the Biopharmaceutical Classification System (BCS) due to its low solubility and high intestinal permeability [74] . However, its aqueous solubility of approximately 0.7 mg/mL -1 is just at the limit for Class I consideration. VCZ presents a minimal inhibitory concentration (MIC) against A. fumigatus of 1 μg/g -1 lung weight [3] . It is marketed as Vfend ® in the form of oral tablets, powder for oral suspension, and powder for perfusion solution. The latter is formulated by means of sulfobutyl ether-β-cyclodextrin (SeβCD) to enhance solubility by formation of an inclusion complex. VCZ has a high oral bioavailability (96 %), which can be drastically reduced by a concomitant meal to reach oral bioavailability of 20 % [75] . It is highly metabolized (only 2 % found unchanged in the urine) by the hepatic cytochrome enzymes P450, 2C19, and to a lesser extent, 2C9 and 3A4. Its metabolites, of which N-oxide represents the majority, have no antifungal actions. Moreover, VCZ exhibits nonlinear pharmacokinetics due to the saturation of its metabolism and its rate of binding to plasma Table 1 Description of formulations developed for inhalation with voriconazole (VCZ) or itraconazole (ITZ), their aerosol performances with the respective inhalation device characterized by the mass median aerodynamic diameter (MMAD) and fine particle fraction (FPF), the excipients used and their approval status for pulmonary drug delivery, and the main properties observed in terms of solubility, dissolution, and/or pharmacokinetics [65] proteins (approximately 58 %). In plasma, its concentration should be kept between 1 μg/mL -1 and 5 μg/mL -1 in order to achieve optimal therapeutic action without severe side effects [76] . VCZ is generally well-tolerated by patients, but side effects may occur, including visual disturbances (photopsia in 20.7 % of patients) and increase hepatic transaminases (observed in 12.4 % of cases) [77] .
Pharmaceutical Development for Inhalation
The first study of voriconazole was performed by Tolman et al., in which a diluted Vfend ® solution was designed for intravenous delivery to the lungs in mice [53] . The concentration of VCZ and SeβCD was adjusted to obtain adequate pH, tonicity, and aerodynamic performance by nebulization (Table 1) . During the pharmacokinetic study, lung VCZ concentration was undetectable 6-8 h after nebulization due to the rapid clearance of this highly permeable drug by absorption into plasma (Table 2) . Indeed, SeβCD increase the aqueous solubility of VCZ, increasing its elimination by absorption. Consequently, high VCZ concentrations after inhalation were detected not only in the lungs but also in the plasma following single-or multiple-dose administration, as revealed by the low lung/blood concentration ratio ( Table 2 ). The authors also evaluated the prophylactic efficacy of nebulized Vfend ® solution in an immunocompromised murine model of IPA caused by A. fumigatus, using nebulized SeβCD solution as a control. Both were delivered from 2 days prior to spore inoculation to 7 days post-inoculation, compared to intravenous amphotericin B deoxycholate solution (AmphB-deox) in a treated group delivered from 1 day after inoculation to 7 days post-inoculation [69] . The prophylactic treatment showed a significant survival difference between the VCZ-treated group and both the control and AmphB-deox groups at 7 days postinoculation as well as 12 days after the end of the therapy (Table 2 ). This significant survival benefit, however, was not linked with fungal burden. Indeed, the fungal burden in mice 8 days post-inoculation was similar for each group, although the control and AmphB-deox groups showed more severe invasive disease and abnormalities than the VCZ group as revealed by lung histopathology. These studies demonstrated not only the prophylactic impact that inhaled VCZ could provide, but also the high systemic exposure when VCZ was delivered by pulmonary route as a highly soluble inclusion complex solution.
In a subsequent study, Beinborn et al. designed dry powders containing either amorphous or crystalline VCZ for inhalation using thin-film freezing, with and without a stabilizing agent (Table 1) , followed by lyophilization [54] . In mice, dry powder containing amorphous VCZ showed significantly higher in vitro dissolution velocity (1.3 times) as well as significantly shorter lung residence compared to the dry powder containing crystalline VCZ ( Table 2 ). As was In vitro burst effect followed by controlled release properties, ability to be aerosolized after co-spray drying with lactose, mannitol and/or leucine [68] A approved for pulmonary administration, DPI dry powder inhaler, FPF fine particle fraction, GRAS generally recognized as safe, MMAD mass median aerodynamic diameter, NR non-reported, NA not approved for pulmonary administration AUC area under the curve, Cmax maximum/ peak concentration, CRL control, HFR high flow rate, LFR low flow, ND non-determined, NR non-reported, rate, Seq equilibrium solubility, t1/2 half-life demonstrated, the amorphous state is thermodynamically less stable than its crystalline counterpart due to a lower ordered system, which increases its aqueous solubility and therefore its dissolution velocity. An increase in aqueous solubility promotes the absorption of this highly permeable drug through the lung epithelium, which shortens its lung residence. The crystalline-based dry powder for inhalation appears to be more suitable for pulmonary delivery, with better aerodynamic performance, lung residence, and systemic exposure (Tables 1 and 2 ). The aqueous solubility of VCZ is at the limit of Class I and passes the lung epithelium easily. Therefore, formulation strategies to control its release rather than its solubility may be more appropriate for pulmonary delivery (Fig. 1) . Sinha et al. developed dry powders for inhalation with controlled-release properties (Table 1) . VCZ was formulated as nonporous and porous nanoparticles with a poly(lactide-co-glycolide) (PLGA), produced by multiple emulsification processes, followed by lyophilization [55] . A drug release study revealed an initial burst effect, delivering 20 % of VCZ within the first 2 h, followed by sustained release for 15 days, with no significant differences between porous and nonporous nanoparticles. The powder aerosol from a mixture of either porous or nonporous nanoparticles and micronized lactose were efficiently generated by a custom-made DPI (Table 1) . Nonporous and porous nanoparticles were delivered in mouse lungs, and VCZ was detectable for least 5 days post-administration. The use of nanoparticles, which limited macrophage phagocytosis, and a sustained-release polymer showed interesting results in terms of increased lung residence. However, PLGA
is not yet approved for pulmonary drug delivery [78] .
Itraconazole
ITZ is a weak base that is practically insoluble in water. Indeed, at neutral pH, its solubility is less than 10 ng/mL -1 , and at pH 1 it is 4 μg/mL -1 . Moreover, ITZ is highly lipophilic, as revealed by its octanol/water (pH 8.1) coefficient of 5.66 [79] . Consequently, it is characterized by low solubility and high permeability through the intestinal membranes, which classifies it as BCS Class II [76] . ITZ presents a MIC against A. fumigatus of 2 μg/g -1 lung weight [3] . It is marketed as Sporanox ® in the forms of capsule, oral, or IV solution. In the solutions, it is solubilized by means of hydroxyl-β-cyclodextrin (HPβCD) [80] . Its bioavailability is erratic due to its acid-dependent solubility. In capsule form, the bioavailability of ITZ varies between 15 and 55 % [3, 81] . In oral solution, the ITZ-HPβCD inclusion complex increases solubility, and therefore bioavailability is increased by 20-30 % [82] . However, the HPβCD-based formulation was associated with a greater number of gastrointestinal disorders. ITZ is primarily metabolized by the cytochrome P450 3A4 in the liver, and its main metabolite, hydroxy-ITZ, has antifungal properties equivalent to ITZ. Once absorbed, this molecule and its metabolite are highly bound to plasma proteins, corresponding to 99.8 % of the administered dose per os. Moreover, ITZ is an important CYP 450 3A4 inhibitor, with strong potential for interactions with other drugs metabolized by this enzyme. The majority of adverse effects associated with ITZ are due to its inhibition. In addition to the interactions, nausea and vomiting (24 %), hepatotoxicity (8.5 %), and skin rash (5-19 %) are the most frequently observed side effects [3] . The minimal plasma concentration of ITZ should be 0.5-1 mg/ mL -1 for either prophylaxis or therapeutic setting [3, 75] .
Pharmaceutical Development for Inhalation
ITZ has a dramatically lower aqueous solubility than VCZ, which has a limiting effect on its pharmacological action and lung residence. Undissolved ITZ particles are rapidly eliminated by the mucociliary escalator and macrophage phagocytosis (Fig. 1 ). As such, formulation strategies are focused primarily on increasing its rate of dissolution. Among the strategies for increasing the dissolution rate of poorly watersoluble drugs [41•] such as ITZ are (i) inclusion complexes into cyclodextrin, (ii) particle size reduction to the nanometer scale, (iii) amorphization of the drug, (iv) optimal wettability, or a combination of the three latter strategies as (v) a solid dispersion, or in lipid-based carriers such as (vi) a nanostructured lipid carrier or (vii) polymeric micelles, as reported in Table 1 . In this review, we focus only on the most advanced and promising pharmaceutical development of ITZ for inhalation, in this case solid dispersions. However, other formulations are also described in Tables 1 and 2 . The first pharmaceutical development was conducted by McConville's research group, which generated inhalable amorphous ITZ nanoparticle-based aggregates by means of spray freezing into liquid (AIPI and AIP2), and compared them to inhalable crystalline ITZ nanoparticle-based aggregates by evaporative precipitation into aqueous solution (CIP) [56] .
In vitro dissolution analysis revealed that the use of both surfactants markedly improved the ITZ dissolution profile, despite its crystalline (CIP) or amorphous (AIP2) state, compared to the use of polysorbate 20 (AIP1) or bulk ITZ (Table 1) . Similar results were observed during the in vivo pharmacokinetic study on mice. Indeed, lung AUC 0-24 h (area under the curve between T=0 and T=24 h, which reflects the lung residence) and lung t 1/2 (terminal half-life, which reflects the ITZ elimination rate) were similar for CIP and AIP2, whereas AIP1 showed higher ITZ elimination, certainly due to a lower dissolution rate and higher elimination by the mucociliary escalator ( Table 2 ). The prophylactic efficacy of CIP and AIP2 was tested by nebulization in an immunocompromised murine model of IPA infected by A. flavus as compared with the Sporanox ® solution delivered orally [72] . All formulations were delivered beginning 1 day prior to spore inoculation, for 12 days. AIP2 showed the highest median survival compared with CIP; both were much higher than the median survival of the Sporanox ® -treated and control groups ( Table 2 ). The superiority of AIP2 appears to be due to higher lung exposure and lower lung elimination compared to that observed with CIP and Sporanox ® , respectively. Vaughn et al. studied the systemic exposure and side effects of pulmonary delivery of AIP2-based dispersion [70, 71, 57] . Higher ITZ concentrations in lung tissue and lower plasmatic concentrations were observed after repeated pulmonary delivery of AIP2 by nebulization in comparison with repeated oral delivery of the Sporanox ® solution (inclusion complex with HPβCD), resulting in a significantly higher lung-to-serum ratio [71] . AIP2 administrated orally showed no difference versus the Sporanox ® solution in terms of lung serum concentrations, but exhibited fewer side effects. Oral administration of the Sporanox ® solution was associated with several side effects, including diarrhea and dehydration due to the presence of HPβCD [70] . Vaughn et al. examined the inflammatory response in mouse lungs, and found no inflammatory response from the pulmonary nebulization of AIP2 or from the excipients poloxamer 407 or polysorbate 80) [57] . Finally, AIP2 was tested by nebulization in an immunocompromised murine model of IPA infected with A. fumigatus [71] . Pulmonary delivery of AIP2 at 30 mg/kg -1 twice a day by nebulization or oral delivery of the Sporanox ® solution at the same dosage three times a day was initiated 2 days before spore inoculation and continued for 14 days. The median survival and percentage of survival at day 12 of AIP2 were significantly higher in comparison with both the Sporanox ® -treated and control groups (Table 2) . Moreover, the AIP2-treated mice showed fewer necrotic foci and vascular lesions, but a similar fungal burden, compared with the control group. The reduction of particle size, use of the amorphous state, and use of an adequate surfactant system for optimal ITZ wettability are interesting tools for increasing the dissolution rate of ITZ and thus achieving much higher lung exposure and residence for optimal prophylactic activity against IPA.
Yang et al. applied another processing technique, ultrarapid freezing, to generate amorphous ITZ nanoparticlebased aggregates (AIN) [58] . This procedure differs from spray freezing into liquid in that it uses rapid freezing of a drug/excipient solution onto a cryogenic substrate of desired thermal conductivity to obtain a solid dispersion/solution. The excipients used were mannitol and lecithin. Mannitol acted as a hydrophilic excipient, aiding water to penetrate and disperse ITZ nanoparticles from the aggregates. Lecithin demonstrated surface-active properties that improved ITZ wettability and consequently the ITZ surface area in contact with the dissolution medium. During a pharmacokinetic study in mice similar to those by Vaughn et al. in 2006 , the authors observed higher lung C max , shorter t max , and a tenfold higher serum C max [70, 58] . These results revealed a significant increase in the absorption constant of ITZ from AIN in comparison with AIP2, which is attributable to the presence of lecithin. Lecithin is composed primarily of phosphatidylcholines, comprising 70-80 % of those occurring in the lung surfactant. Exogenous phospholipids are known to increase absorption by decreasing bilayer stability [83] . The authors posited that appropriate size reduction, supersaturated ITZ concentration, and the presence of absorption enhancers such as lecithin were responsible for the sizable increase in ITZ absorption rate.
In order to evaluate the impact of supersaturated ITZ concentration, Yang et al. compared the dissolution improvement in supersaturation conditions of AIN with the dissolution of crystalline ITZ nanoparticles produced by wet-milling (CIN) in a similar surface area [60] . The supersaturation of the simulated lung fluid with AIN was 27 times greater than with CIN after 15 and 30 min, the latter its saturation solubility equilibrium (Seq). The supersaturation concentration then progressively decreased to seven times after 2 h and five times after 24 h. An in vivo pharmacokinetic study on rats revealed a similar lung deposition after nebulization of both formulations, with similar elimination after 24 h. However, the plasma Cmax and AUC0-24 h of ITZ were nearly four times higher for AIN than CIN. These results revealed that there was a higher amount of ITZ dissolved in the lung, leading to higher absorption into the blood, while the ITZ from CIN was mainly undissolved and eliminated by the non-absorptive clearance systems such as the mucociliary escalator. Yang et al. evaluated the impact of lecithin in ITZ absorption by comparing lung and serum pharmacokinetics from a nebulized solution of amorphous ITZ-based inclusion complex with HPβCD (ICD) to that from AIN [60] . Suitable aerodynamic performance was obtained for ICD and AIN (Table 1) . Lung pharmacokinetic data revealed similar C max and lower elimination, leading to slightly higher lung AUC 0-24 h for ICD in comparison with AIN (Table 2) . With regard to serum pharmacokinetic data, AIN showed higher systemic exposure than ICD, with a lower t 1/2 into the blood from the lung, leading to a higher AUC 0-24 h (Table 2 ). In fact, despite the fact that the dissolution step of AIN was not encountered with ICD, higher ITZ concentrations were detected over time in serum than from ICD, demonstrating an increase in the absorption rate related to an increase in permeability, with the latter due to the permeation-enhancing properties of lecithin. From these studies, Yang et al. demonstrated the advantage of the dissolution rate of the amorphous state of ITZ in the dissolved portion of ITZ in the lung, although resulting also in higher elimination by absorption. In addition, they demonstrated the permeability-enhancing properties of lecithin.
Duret et al. recently conducted a study in which they produced solid-dispersion-based dry powders for inhalation. This was accomplished via spray-drying, with the aim of increasing the ITZ dissolution rate by reducing the size to nanometer scale, using the amorphous state, and generating optimal wettability/hydrophilic environment by using surfactant and/or hydrophilic matrix. The spray-drying process is an easily scaled-up one-step process, contrary to the method of spray-freezing into liquid. Spray-drying converts atomized liquid droplets to respirable dried microparticles of 1-5 μm. Compared to the use of liquid formulations aerosolized by nebulizers, the use of dry powder agents for inhalation could reduce administration time and environmental drug propagation, increase longterm drug stability and lung-deposited dose, and could be produced with disposable devices, reducing maintenance. Solid dispersions were produced from hydroalcoholic solutions containing amorphous ITZ and mannitol, with and without surfactant (tocopherol polyethylene 1000 succinate or Phospholipon ® 90H) [61, 62] . The resulting dried microparticles demonstrated good aerodynamic performances and improved ITZ dissolution properties (Tables 1 and 2 ). The presence of amorphous ITZ in the mannitol matrix increased the dissolution profile significantly compared with crystalline or amorphous ITZ without hydrophilic matrix. Moreover, the presence of 10 % of Phospholipon ® 90H related to ITZ weight had a significant positive impact on the dissolution profile versus solid dispersions without Phospholipon ® 90H [62] . A pharmacokinetic study in mice was performed to evaluate solid dispersions made with crystalline ITZ (CI) or amorphous ITZ, with (AI90H) and without (AI) 300 % Phospholipon ® 90H, in relation to ITZ weight [63•] . In terms of solubility, IC showed no improvement, while AI and AI90H demonstrated supersaturated solubility 45 and 50 times greater than Seq at 30 and 5 min, respectively. However, supersaturation levels decreased over time to lower values (44 and 87 ng/ml -1 , respectively, at 24 h). Consequently, the dissolution profiles of AI and AI90H were significantly improved in comparison with CI. In addition, the presence of Phospholipon ® 90H greatly improved the dissolution profile of AI90H compared to AI. Lung and plasma pharmacokinetic studies revealed higher lung AUC 0-24 h for AI compared to CI and AI90H (Table 2) corresponding to dissolved and undissolved portions of ITZ in the lungs. The plasma concentrations indicated that the dissolved portion of ITZ was able to be absorbed.
The highest plasma exposures were seen with AI and AI90H compared with CI (Table 2) . AI provided the best balance between sufficient lung residence and dissolution rate of ITZ. In fact, the elimination by absorption with AI90H was too rapid due to the excessive dissolution rate of ITZ, and CI showed rapid elimination by the mucociliary escalator due to insufficient dissolution, as revealed by respective lung t 1/2 ( Table 2) . Moreover, the presence of Phospholipon ® 90H (saturated phosphatidylcholine, including 85 % of 1,2-distearoylsn-glycero-3-phosphocholine and 15 % of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine) not only increased the ITZ dissolution rate, but it also increased ITZ permeability through the lung. Lastly, Duret et al. tested the prophylactic efficacy of AI in an immunocompromised murine model of IPA infected with A. fumigatus [73] . AI at 5 mg/kg -1 every 48 h was insufflated into mouse lungs and compared with a non-treated group and a group treated orally with 12.5 mg/kg -1 of VCZ twice a day. All treatments began 2 days prior to spore inoculation and lasted for 7 days. Survival curves showed a significant increase in survival rate in the AI -treated group versus the non-treated and oral VCZ-treated groups. AI showed similar prophylactic efficacy, with a higher survival percentage than the conventional oral VCZ treatment (Table 2) .
Conclusions
The inhalation of triazoles such as ITZ and VCZ appears to hold promise for the prevention and treatment of IPA by controlling dissolution characteristics (improving in the case of ITZ and prolonging release in the case of VCZ) and by avoiding the clearance systems for insoluble ITZ and for controlled-release VCZ delivery systems. Moreover, pulmonary administration allows for systemic exposure and thereby reduces side effects or drug-drug interactions, while increasing therapeutic activity by directly targeting the infection locus in situ. The residence time of the solubilized drug in the lungs is the cornerstone of formulation strategies to strike the appropriate balance between pharmacological action and elimination. According to established guidelines, this strategy may be also applied to posaconazole and fluconazole to prevent or treat other kinds of aspergillosis or other pulmonary fungal infections such as candidiasis, histoplasmosis, mucormycosis, cryptococcosis, blastomycosis, and coccidioidomycosis.
